Prostate Cancer is a type of malignancy, occurs in the prostate gland that is a part of male reproductive system.
Prostate Cancer Epidemiological Segmentation
The Epidemiological Segmentation of Prostate Cancer in 7MM from 2017 to 2030 is segmented as:-
- Total Prevalent Cases of Prostate Cancer
- Total Diagnosed Cases of Prostate Cancer
- Total Diagnosed Cases of Prostate Cancer patients by Clinical Stages
- Prostate cancer cases by clinical stages –
*Localized/ locally advanced cases (Stage I-III)
*Biochemical recurrence/ progressive cases
*Metastatic cases
- Age Group-specific Cases of Prostate Cancer –
*≤ 54 years;
*55-64 years;
*65-74 years;
*75-84 years;
*>84 years
- Prostate Cancer cases by Non-Metastatic CSPC/ CRPC and metastatic CSPC/ CRPC -
*Non-metastatic castrate-sensitive prostate cancer (nmCSPC*/ nmHSPC*)
*Non-metastatic castrate-resistant prostate cancer (nmCRPC*)
*Metastatic castrate-sensitive prostate cancer (mCSPC/ mHSPC)
*Metastatic castrate-resistant prostate cancer (mCRPC)
- Total Treated Cases of mHSPC/CSPC and CRPC
- Total Treated cases of Non-Metastatic CSPC/HSPC and CRPC
* Hormone-Sensitive Prostate Cancer (HSPC)
* Castrate-Resistant Prostate Cancer (CRPC)
* Castrate-Sensitive Prostate Cancer (CSPC)
- Total Prevalent cases of Prostate Cancer in 7MM in 2020 were7,494,882
- Total Prevalent cases of Prostate Cancer in the United States in 2020 were 3,478,728
The Market Size of Prostate Cancer is growing at 8.1% CAGR for the study period of 2017 to 2030.
Prostate Cancer Market Drivers
- Increasing Use of Biomarker Testing
- Rising Geriatric Population and High Prevalence Rate of Prostate Cancer
- Surge in Awareness regarding the Treatment of Prostate Cancer
- Increase in Demand for Prostate Cancer Treatment Products
Prostate Cancer Market Barriers
- The complex issue of companion diagnostics
- Cost Constraints
- Entry Barrier
Prostate Cancer Emerging Drugs
The emerging drugs of the Prostate Cancer market are
- Lynparza (Olaparib)
- Opdivo (nivolumab)
- 177Lu-PSMA-617
- Relugolix
- HC-1119
- Seviteronel (VT-464)
- PROSTVAC-V/F
- ODM-208
- Sacituzumab Govitecan (IMMU-132)
- Keytruda (Pembrolizumab/MK-3475)
- Ipatasertib (RG7440)
- Talazoparib
- Capivasertib (AZD5363): AZD4635
- PRX302 (topsalysin): Pamiparib (BGB-290)
- Enoblituzumab (MGA271)
- Tisotumab Vedotin
- Dupilumab
- Rubraca (Rucaparib)
- Niraparib
- Proxalutamide (GT0918)
- Abemaciclib (LY2835219)
- Tomivosertib (eFT508)
- Onvansertib
- RV001V
- ProstAtak
And many others.
Prostate Cancer Key Players
The key players in the Prostate Cancer market are
- AstraZeneca
- Merck Sharp & Dohme
- Bristol-Myers Squibb
- Novartis
- Myovant Sciences
- Takeda
- Hinova Pharmaceuticals
- Innocrin Pharmaceutical
- Bavarian Nordic
- Orion Pharma
- Immunomedics
- Hoffmann-La Roche
- Pfizer
- Astellas Pharma
- Sophiris Bio
- BeiGene
- MacroGenics
- Genmab
- Regeneron Pharmaceuticals
- Clovis Oncology
- Janssen Research & Development
- Suzhou Kintor Pharmaceutical
- Eli Lilly and Company
- eFFECTOR Therapeutics
- Trovagene
- RhoVacz
- Advantagene
And many others.
Stay tuned for latest updates on Prostate Cancer treatment landscape